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Summary
Background: Non-invasive positive pressure ventilation (NPPV) for acute heart failure (AHF) is
increasingly used to avoid endotracheal intubation (ETI). We therefore reviewed our experience
using respirator management in the emergency room for AHF, and evaluated the predictive
factors in the success of NPPV in the emergency room.
Methods and results: Three-hundred forty-three patients with AHF were analyzed. The AHF
patients were assigned to either BiPAP-Synchrony® (B-S; Respironics, Merrysville, PA, USA)
period (2005—2007, n = 176) or BiPAP-Vision® (B-V; Respironics) period (2008—2010, n = 167). The
rate of carperitide use was signiﬁcantly increased and dopamine use was signiﬁcantly decreased
in the B-V period. The total length of hospital stay was signiﬁcantly shorter in the B-V period.
AHF patients were also assigned to a failed trial of NPPV followed by ETI (NPPV failure group) or
an NPPV success group in the emergency room for each period. NPPV was successfully used in
48 cases in the B-S period, and in 111 cases in the B-V period. Fifty-seven ETI patients included
45 direct ETI and 11 NPPV failure cases in the B-S period, and 16 ETI patients included 10 direct
ETI and 6 NPPV failure cases in the B-V period. The pH values were signiﬁcantly lower in the
NPPV failure than in the NPPV success for both periods (7.19± 0.10 vs. 7.28± 0.11, B-S period,
p < 0.05; 7.05± 0.08 vs. 7.27± 0.14, B-V period, p < 0.001). A pH value of 7.20 produced the opti-
mal balance in the B-S period, while that of 7.03 produced the optimal balance in B-V periods by
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the ROC curve analysis. The cutoff value of pH was lower in the B-V period than in the B-S
period.
Conclusions: This predictive value provides successful estimates of NPPV with a high sensitivity
c blood gas level was above 7.03 pH when using the B-V system.
ardiology. Published by Elsevier Ltd. All rights reserved.
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each of the doctors to suit each individual patient’s condi-
tion. There were no limitations for the selection conditionsand speciﬁcity, and the aorti
© 2011 Japanese College of C
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atients with acute heart failure (AHF) present with a
orm of hypoxemic acute respiratory failure caused by
cute pulmonary edema. Standard therapy for patients with
HF includes conservative medical therapy and respira-
ory management. Patients with severe AHF often require
ndotracheal intubation (ETI), and standard respiratory
anagement previously called for mechanical ventilation.
he potential beneﬁt of non-invasive positive pressure ven-
ilation (NPPV), in which pressure support and positive end
xpiratory pressure are delivered via face mask or nasal
ask, was recognized over the previous decades as a new
ode of ventilator management which dispensed with ETI
1—6]. Meta-analysis studies have speciﬁcally reported on
PPV in patients with AHF [7—11] and NPPV signiﬁcantly
ecreased mortality when compared to rates in patients who
eceive standard medical treatment and mechanical ven-
ilation [7]. The European Society of Cardiology presented
n guidelines that continuous positive airway pressure was
he ﬁrst line of treatment before mechanical ventilation
nd conservative therapy including diuresis, nitroglycerin,
nd dobutamine [12]. NPPV therefore is increasingly used
s a means to avoid ETI and its attendant complications in
atients with AHF.
Thus, NPPV has garnered attention for the treatment of
ypoxemic AHF. However, there are institutions which have
ot implemented NPPV because physicians lack experience
ith this method [13]. Despite recent evidence, the rate
f NPPV use as an acute respiratory strategy was 69.5%
n patients who required mechanical ventilation according
o the ADHERE registry [14] and approximately 20% in all
atients with AHF from the ongoing Japanese ATTEND reg-
stry [15].
The success of NPPV is due to the skill of the medical
eam and the experience of the physician in the emer-
ency setting. In some studies NPPV management success
redictors were identiﬁed in patients with acute respira-
ory failure including chronic obstructive pulmonary disease
16,17]. These studies indicated that patients with a bet-
er neurologic status and who have not developed severe
cid—base or gas exchange derangements are more likely to
ucceed. However, the recommended guidelines for NPPV
se according to clinical and blood gas criteria have not been
ell studied in patients with AHF. We herein found that the
requency of NPPV increased rapidly in recent years through
he use of the BiPAP Vison® (B-V) system (Respironics, Mer-
ysville, PA, USA) in which the inspired oxygen concentration
ould be enriched to 100%. The aims of our study were
o evaluate the efﬁciency of the B-V system in comparison
o the BiPAP Synchrony® (B-S) system (Respironics), and to
valuate the predictive factors for the success of NPPV in
a
m
g
5mergency room in patients with AHF based on the use of
ach system.
ethods
ubjects
e analyzed 343 patients with AHF who were admitted
o the intensive care unit of Chiba Hokusoh Hospital, Nip-
on Medical School between January 2005 and September
010. AHF was deﬁned as either new-onset HF or decom-
ensation of chronic HF with symptoms sufﬁcient to warrant
ospitalization [18]. HF was diagnosed based on the Fram-
ngham criteria for a clinical diagnosis of HF, based on the
atisfaction of 2 major criteria or 1 major and 2 minor
riteria [19]. All patients had a New York Heart Asso-
iation (NYHA) functional class of either Class III or IV.
atients with HF caused by acute coronary syndrome were
xcluded. The patients who had already undergone ETI prior
o admission or who had immediately received NPPV man-
gement in the emergency room before any examinations
ere also excluded. Any patients who were changed to res-
iratory management because of a worsening respiration
fter leaving the emergency room were excluded as well.
he speciﬁc strategy of respiratory management and the
edical treatment were chosen by each individual doctor
articipating.
evices
he B-S and B-V systems were used for pressure support
nd positive end-expiratory pressure, delivered via face
ask or nasal mask for NPPV. The continuous positive air-
ay pressure mode (only positive end-expiratory pressure)
r bi-level positive airway pressure mode (pressure support
nd positive end-expiratory pressure) could be selected with
oth systems. However, the inspired oxygen concentration
ould be increased to 100% with the B-V system, but not
he B-S system. The inspired oxygen concentration could
e increased to 60% using the B-S system. The B-S sys-
em was in use for NPPV in emergency rooms from 2005
o 2007, and the B-V system has been in use from 2008
o 2010. The bi-level positive airway pressure mode or the
ontinuous positive airway pressure mode was chosen byccording to the mode for NPPV and the selection of mask
anagement.
Almost all patients underwent transthoracic echocardio-
raphy upon admission and after HF stabilization (Sonos
500, Hewlett Packard, Palo Alto, CA, USA or Vivid I, GE
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Table 1 Comparison of the patient backgrounds.
B-S period
(2005—2007) (n = 176)
B-V period
(2008—2010) (n = 167)
All (2005—2010)
(n = 343)
p-value
Age (years) 71.9± 10.7 72.1± 11.7 72.0± 11.2 n.s.
Gender (male/female) (cases) 120/56 122/45 242/101 n.s.
NYHA (III/IV) (cases) 43/133 36/131 79/264 n.s.
LVEF (%) on admission 35.7± 17.5 36.7± 16.4 36.0± 16.8 n.s.
BNP (pg/ml) 1281.1± 1566.1 1027.4± 1083.8 1146.3± 1335.5 n.s.
SBP (mmHg) 161.8± 36.7 164.5± 39.0 163.1± 37.8 n.s.
Pulse (beats/min) 118.5± 30.6 108.7± 30.0 114.3± 29.6 < 0.001
Etiology of heart failure (cases)
Ischemic heart disease 73 75 148
Cardiomyopathy 34 30 64
Hypertensive heart disease 31 28 59
Valvular disease 35 28 63
Others 3 6 9
Past medical history
Hypertension (y/n) 121/55 137/30 258/85 0.007
Diabetes mellitus (y/n) 102/74 97/70 198/145 n.s.
Hyperlipidemia (y/n) 95/81 83/84 178/165 n.s.
Amount of O2 inhalation (L) 8.56± 3.24 8.55± 3.32 8.55± 3.27 n.s.
Ph 7.28± 0.15 7.28± 0.16 7.28± 0.15 n.s.
PCO2 (mmHg) 51.4± 19.1 50.3± 22.6 50.9± 20.9 n.s.
PO2 (mmHg) 98.1± 52.1 107.7± 66.3 102.8± 59.6 n.s.
SaO2 (%) 91.5± 7.8 91.7± 10.0 91.6± 8.9 n.s.
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction measured by echocardiogram at emergency room; BNP, brain
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hnatriuretic peptide; SBP, systolic blood pressure; B-S, BiPAP Synchr
(2008—2010).
Yokokawa Medical, Tokyo, Japan). Left ventricular ejection
fraction (LVEF) was calculated using the Teicholz method or
Simpson’s methods.
Procedures
From the information collected, we examined (1) the fre-
quency of NPPV usage as a respiratory strategy in the
emergency room between the two periods (B-S period:
2005—2007, n = 176; B-V period: 2008—2010, n = 167), and
also examined (2) any differences in the patients’ charac-
teristics and treatments between the two time periods.
The AHF patients who needed mechanical ventilation
were also divided to a failed trial of NPPV followed by
ETI (NPPV failure group), direct ETI group, and an NPPV
success group according to the differences in the respira-
tory management in the emergency room for each period.
We examined (3) the differences in the clinical information
including the vital signs [blood pressure (BP), heart rate,
body temperature, respiratory rate], and arterial blood
gases (pH, PCO2, PO2, SaO2) before determining the appro-
priate respiratory management between the NPPV failure
groups and the NPPV success groups in each period.Statistical analysis
All numerical data are expressed as the means± standard
deviation. Variables were compared using the chi-square
I
w
O
S
sB-V, BiPAP-Vision; p-value; B-S period (2005—2007) vs. B-V period
est, and a p-value of less than 0.05 was deﬁned as statis-
ically signiﬁcant. The signiﬁcant factors for distinguishing
etween the ETI and NPPV groups were determined based on
multivariate logistic regression model. Receiver-operating
haracteristic (ROC) curves were calculated to predict the
utoff value. The sensitivity, speciﬁcity, and area under ROC
urves (AUC) were computed using the SPSS 14.0J software
ackage (SPSS Japan Institute, Tokyo, Japan).
All data were statistically analyzed using the StatView 5
oftware package (SAS Institute, Cary, NC, USA), and SPSS
4.0J.
esults
atient characteristics
able 1 shows that patient cohort was composed of 70.6%
ales with a mean age of 72.0± 11.2 years. One hun-
red and forty-eight (43.1%) patients had ischemic heart
isease, and 195 (56.9%) patients had non-ischemic heart
iseases including cardiomyopathy (n = 64), hypertensive
eart disease (n = 59), valvular disease (n = 63), and other
eart diseases (n = 9). Most patients were in the NYHA class
V (77.0%), and the average LVEF values upon admission
ere 36.0%. Average arterial blood gas was as following:
2, 8.55 L; pH, 7.28; PCO2, 50.9mmHg; PO2, 102.8mmHg;
aO2, 91.6%. Almost all of these clinical values were not
tatistically different between the B-S and B-V periods.
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Figure 1 Time-dependent changes in respiratory manage-
ment in the emergent room for patients with AHF. The rate
of NPPV use at emergency room increased yearly, and ETI
decreased. The ETI group had 57 patients (32.4%), the NPPV
group 48 patients (27.2%) and O2 inhalation group 71 patients
(40.4%) in the BiPAP-Synchrony period. The ETI group contained
16 patients (9.6%), the NPPV group 111 cases (66.5%) and O
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nhalation group 40 patients (23.9%) in the BiPAP-Vision period.
TI, endotracheal intubation; NPPV, non-invasive positive pres-
ure ventilation.espiratory management
ig. 1 shows the rate of patients under respiratory manage-
ent, including ETI, NPPV, and O2 inhalation while in our
nstitution. The frequency of NPPV use in the emergency
i
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Table 2 Comparison of patient characteristics and medications d
B-S p
(200
LVEF (%) before discharge 42.3
ICU hospitalization (days) 6.3±
Total hospitalization (days) 38.4
Respirator management in ER (cases)
Ventilator 57
NPPV 48
O2 inhalation 71
Duration of ventilator (h) 69.1
Duration of NPPV (h) 15.7
Medication (cases)
(Acute phase) Furosemide (y/n) 166/
Nitroglycerin (y/n) 153/
Nicorandil (y/n) 8/16
Carperitide (y/n) 111/
Dopamine (y/n) 46/1
Dobutamine (y/n) 45/1
(Acute-chronic phase) ACE-I/ARB (y/n) 127/
Spironolactone (y/n) 100/
-Blocker (y/n) 104/
Prognosis (cases)
Alive/dead 168/
LVEF, left ventricular ejection fraction; ICU, intensive care unit; ER, em
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin recep
period (2005—2007) vs. B-V period (2008—2010).A. Shirakabe et al.
oom increased yearly. The ETI group included 57 patients
32.4%), NPPV 48 patients (27.2%) during the B-S period.
n the B-V period, the rate of ETI decreased in 16 cases
9.6%), and the rate of NPPV increased for 111 patients
66.5%).
atient characteristics and medications during
ospitalization
able 2 illustrates the differences in the patients’
haracteristics during hospitalization between the two peri-
ds. The total hospitalization was signiﬁcantly shorter
n the B-V period (29.8± 37.8 days) than in the B-S
eriod (38.4± 39.9 days) (p < 0.05). The majority of patients
93.3%) received intravenous loop diuretics during the
cute phase. Nitroglycerin and carperitide were admin-
stered in 77.6% and 69.7% of patients, respectively. In
ontrast, dopamine and dobutamine were used in 20.4%
nd 22.2% of patients, respectively. Angiotensin-converting
nzyme inhibitors or angiotensin II receptor blockers were
dministered to 232 patients (67.6%), spironolactone was
dministered to 179 (52.2%) patients, and -blockers were
dministered to 187 (54.5%) patients. The administration
f nitroglycerin signiﬁcantly (p < 0.001) decreased, while
he administration of nicorandil signiﬁcantly (p < 0.001)
ncreased during the B-V period in comparison to the B-
period. Furthermore, the administration of carperitide
igniﬁcantly (p < 0.05) increased and the administration of
opamine signiﬁcantly (p < 0.05) decreased during the B-V
eriod in comparison to the B-S period.
uring hospitalization.
eriod
5—2007) (n = 176)
B-V period
(2008—2010) (n = 167)
p-value
± 16.2 45.3± 16.5 n.s.
8.9 5.6± 7.1 n.s.
± 39.9 29.8± 37.8 0.044
16
111
40
± 62.1 84.7± 109.5 n.s.
± 14.9 20.9± 16.3 n.s.
10 154/13 n.s.
23 113/54 <0.001
8 35/132 <0.001
65 128/39 0.009
30 24/143 0.011
31 31/136 n.s.
49 105/62 n.s.
76 79/88 n.s.
72 78/89 n.s.
8 162/5 n.s.
ergency room; NPPV, non-invasive positive pressure ventilation;
tor blocker; B-S, BiPAP Synchrony; B-V, BiPAP-Vision; p-value, B-S
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Table 3 Comparison of the vital signs and arterial blood gas between the success and failure of NPPV management in the
emergency room.
B-S period (2005—2007) NPPV success (n = 48) NPPV failure (n = 11) p-value
Vital sign
SBP (mmHg) 158.1 ± 31.6 179.3 ± 28.2 0.046
HR (beats/min) 125.1 ± 30.0 135.1 ± 26.7 n.s.
BT (◦C) 36.0 ± 1.0 35.9 ± 1.1 n.s.
RR (time/min) 33.5 ± 7.2 33.4 ± 10.6 n.s.
Arterial blood gas
pH 7.28 ± 0.11 7.19 ± 0.10 0.008
PCO2 (mmHg) 49.8 ± 15.3 62.4 ± 13.9 0.015
PO2 (mmHg) 98.2 ± 56.7 80.8 ± 29.4 n.s.
SaO2 (%) 91.7 ± 6.7 88.9 ± 6.4 n.s.
B-V period (2008—2010) NPPV success (n = 111) NPPV failure (n = 6) p-value
Vital sign
SBP (mmHg) 168.4± 39.0 147.3± 62.8 n.s.
HR (beats/min) 112.0± 27.9 114.7± 26.8 n.s.
BT (◦C) 35.8± 2.9 36.5± 1.0 n.s.
RR (time/min) 33.5± 6.5 35.2± 9.5 n.s.
Arterial blood gas
pH 7.27± 0.14 7.05± 0.08 <0.001
PCO2 (mmHg) 51.2± 19.3 82.0± 51.4 <0.001
PO2 (mmHg) 110.1± 73.2 90.4± 29.3 n.s.
RR,
NPP
T
c
O
t
p
cSaO2 (%) 91.2± 11.1
SBP, systolic blood pressure; HR, heart rate; BT, body temperature;
B-S, BiPAP Synchrony; B-V, BiPAP-Vision; p-value, NPPV success vs.
Information before deciding respiratory
management
Fifty-seven ETI patients included 45 in the direct ETI group,
11 in the NPPV failure group, and 1 with O2 inhalation fail-
ure in the B-S period. Sixteen ETI group patients were also
divided into 10 direct ETI group and 6 NPPV failure group in
the B-V period. Success rate of NPPV increased from 81.4%
to 94.9%. Table 3 shows the value of vital signs and arte-
rial blood gas before respiratory management was started.
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Figure 2 Receiver-operating characteristic (ROC) curves for pH.
sensitivity and speciﬁcity (81.2% and 64.5%) in the BiPAP-Synchrony
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characteristic (ROC) curves.86.3± 12.2 n.s.
respiratory rate; NPPV, non-invasive positive pressure ventilation;
V failure.
he BP was signiﬁcantly higher in the NPPV failure group
ompared with the NPPV success group in the B-S period.
ther vital signs were not signiﬁcantly different between
he NPPV failure group and NPPV success group in either
eriod. The arterial blood gas value for pH was signiﬁ-
antly lower in the NPPV failure group than in the NPPV
uccess group for both periods (7.19± 0.10 vs. 7.28± 0.11,
-S period, p < 0.05; 7.05± 0.08 vs. 7.27± 0.14, B-V period,
< 0.001). The PCO2 values were signiﬁcantly higher in the
PPV failure group than in the NPPV success group for
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(A) pH value of 7.20 produced the optimal balance between
period. (B) However, a pH value of 7.03 produced the opti-
n the BiPAP-Vision period. AUC, area under receiver-operating
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oth periods (62.4± 13.9mmHg vs. 49.8± 15.3mmHg, B-
period, p < 0.05; 82.0± 51.4mmHg vs. 51.2± 19.3mmHg,
-V period, p < 0.001). The cutoff value for pH was deter-
ined according to an ROC curve analysis to distinguish the
alues of NPPV failure group and NPPV success group for both
eriods. A pH value of 7.20 produced the optimal balance
etween sensitivity and speciﬁcity (81.2% and 64.5%; AUC
.725, p < 0.05) in the B-S period (Fig. 2A). Moreover, a pH
alue of 7.03 produced the optimal balance between sensi-
ivity and speciﬁcity (92.8% and 66.7%; AUC 0.910, p < 0.001)
n the B-V period (Fig. 2B).
iscussion
he rate of NPPV use increased rapidly after the introduction
f the B-V system, during which the inspired oxygen concen-
ration could be increased to 100%. Moreover, the success
ate of NPPV also increased by the use of B-V system. The
dministration of carperitide which was reported to lead to
etter prognosis in AHF [20] signiﬁcantly increased, and the
dministration of dopamine which was associated with poor
rognosis in AHF [21] signiﬁcantly decreased. This ﬁnding
ndicated that we might be able to successfully maintain
he BP levels because we did not need to administer any
xcessive sedation due to the reduction of ETI. Nicorandil
as been approved for use since 2007 in Japan for patients
ith AHF, therefore, the administration of nitroglycerin sig-
iﬁcantly decreased and the administration of nicorandil
igniﬁcantly increased, however, the use rate of a vasodila-
or did not signiﬁcantly differ between the two periods. The
otal length of hospital stay was shorter when increasing the
PPV, namely from 81.4% to 94.9% with ventilator support.
ur data therefore suggest that NPPV is an effective strategy
or the treatment of AHF.
The present study indicates that patients who have
ot developed either severe acid—base or gas exchange
erangements are more likely to be successfully treated
nder NPPV management. We suggest that the management
f NPPV would be successful with high sensitivity and speci-
city for patients whose aortic blood gas pH levels lie above
.03 with the use of the B-V system. There have been a few
eports that attempted to establish recommended guide-
ines according to the blood gas criteria for the initial use of
PPV in patients with AHF.
vidence of NPPV in AHF as respiratory
anagement
HF patients present with a form of hypoxemic acute res-
iratory failure caused by acute pulmonary edema (veriﬁed
y chest X-ray), which is accompanied by severe respiratory
istress, including crackles over the lung and orthopnea.
xygen saturation is usually lower than 90% of ambient air
rior to treatment. NPPV, which is the combination of pres-
ure support and positive end-expiratory pressure delivered
ia face mask or nasal mask, has in recent years increased
n usage to avoid ETI and its attendant complications in
atients with AHF. ETI is associated with a considerable risk
f morbidity, including upper airway trauma, nosocomial
neumonia, and sinusitis. This procedure may prolong inten-
ive care unit and hospital stays, as additional time may be
o
f
d
l
(A. Shirakabe et al.
ecessary for weaning from ventilation and the treatment
f additional complications.
The guidelines on the diagnosis and treatment of AHF
rom the European Society of Cardiology consider the strat-
gy of ventilator support without ETI in the treatment of
atients with AHF resistant to standard medical therapy
12]. The efﬁciency of continuous positive airway pres-
ure was reported by a randomized controlled trial in
atients with cardiogenic pulmonary edema [1,2,4,5,22].
he investigators measured PaO2/FiO2 ratio as an indicator
f oxygenation, aortic blood gas, and hemodynamics, which
ere all improved by continuous positive airway pressure
1,2,4,5], and the rate of ETI was decreased by positive
irway pressure [1,5,6]. Takeda et al. reported that the
ulmonary artery wedge pressure was signiﬁcantly lower,
nd the cardiac index was higher in comparison to patients
reated with oxygen [4]. In more recent studies, it was also
eported that the efﬁciency of bi-level positive airway pres-
ure was improved, as demonstrated by clinical information
ncluding blood pressure, heart rate, respiratory rate, and
rterial blood gases (pH, PCO2, PO2, SaO2). The rates of ETI
lso decreased by the use of bi-level positive airway pres-
ure [23,24]. Therefore, NPPV, which is a ventilator support
ithout ETI and which uses bi-level positive airway pressure
nd continuous positive airway pressure, has proven its use
n clinical situations.
The improvement in mortality by the use of NPPV and
he death rates in the intensive care unit and hospital were
ecreased due to an increased use of NPPV in patients with
cute exacerbation of chronic obstructive pulmonary dis-
ase [25]. Some meta-analysis has reported on NPPV in
HF patients, and these studies also demonstrated the efﬁ-
iency of NPPV, deﬁned as the effect of improvement of the
atients’ prognosis [7—11].
he use of NPPV in emergency settings
n spite of mounting evidence demonstrating NPPV efﬁ-
acy, the opportunity for NPPV use was unexpectedly low
ith use of the AHF registry, such as the ongoing Japanese
TTEND registry [15]. This is one reason that physicians
ere inexperienced with this method. If patients devel-
ped signs of discomfort or noncooperation, physicians can
isunderstand that these patients are non-responders and
mmediately reconciled these patients to continue NPPV
13]. In other cases, if physicians only slowly implement
PPV, then physicians may thus miss an opportunity to use
PPV effectively since respiratory failure is well known to
dvance rapidly in the emergency setting. NPPV success
s largely due to the skill of the medical team in treating
atients. Physicians must consider many factors, including a
atient’s diagnosis, the reversibility of the respiratory fail-
re, the patient’s clinical characteristics, and the risk of
ailure; the judgment depends largely on physician experi-
nce.
In the ﬁeld of acute respiratory failure including chronic
bstructive pulmonary disease, some predictors of success
or NPPV have been identiﬁed by several studies. These pre-
ictors include synchronous breathing, intact dentition, a
ower APACHE score, and a good initial response to NPPV
correlation of pH, reduction in respiratory rate, and reduc-
lure
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tion in PaCO2) [26,27]. Patients with better neurologic
conditions and who are more cooperative, who can pro-
tect their airways without severe acid—base or gas exchange
derangement together have a higher chance of success fol-
lowing NPPV treatment. However, a report predicting the
success of NPPV in patients with AHF in emergency depart-
ments appeared to be rare. In the present examination,
we demonstrated the success of NPPV use to increase by
introducing the B-V system, in which the inspired oxygen
concentration could be set to 100%. In a previous study, it
was pointed out that the use of NPPV, in which the inspired
oxygen concentration could not be set to 100% leads, had
no effect on the short-term mortality [28]. Our ﬁndings sug-
gest that it might be able to avoid ETI in patients with a pH
greater than 7.03, and with a statistically high sensitivity
and speciﬁcity, by using the B-V system. In our institu-
tion, continuous positive airway pressure was tried on all
patients. While patients were not cooperative for face mask
attachment, it was strongly attached by many physicians or
bi-level positive airway pressure was achieved with a small
amount of sedation. If a patient exhibited severe neurologic
conditions with acidosis, bi-level positive airway pressure
was attempted ﬁrst.
Several studies also have found that a patient’s initial
response to NPPV following 1 h of treatment (as demon-
strated by improvements in pH, PaCO2, and levels of
consciousness) are associated with greater rates of success.
These studies also indicated that there is a window of oppor-
tunity for initiating NPPV [16,25,29]. Data are not shown in
the present study, but non-responders of NPPV continued to
demonstrate a severely acidemic state. We therefore rec-
ommend that NPPV should be used ﬁrst by means of a B-V
system if the pH levels lie above 7.03; however, if the patient
becomes severely acidemic despite receiving NPPV therapy,
then the patient should be immediately switched to ETI.
Study limitations
There are several limitations associated with this study.
First, the main limitation was the small number of patients
included in each of the groups. Therefore, the conclusion
that NPPV should be used ﬁrst by means of a B-V system if
the pH levels lie above 7.03 is a relatively premature one.
Second, this is a retrospective study, the device for respira-
tory management was decided by each physician, and there
were no limitations as to the decision of respiratory manage-
ment. There is a natural physician’s bias. Third, the present
study was a single center study, the patients’ bias might
exist. For example, systolic BP was relatively high compared
with other HF registries and the rate of new-onset HF was
high at 60.7%.
Conclusions
The frequency and success of NPPV use increased rapidly
with use of the B-V system at our institution. Distinguishing
whether to utilize NPPV or ETI before determining on the
optimal respiratory management was mainly based on the
pH levels. NPPV will be successful with both a high sensitivity
and speciﬁcity if the aortic blood pH gas levels are above
7.03 before using the B-V system.
[113
eferences
[1] Räsänen J, Heikkilä J, Downs J, Nikki P, Väisänen I, Viitanen
A. Continuous positive airway pressure by face mask in acute
cardiogenic pulmonary edema. Am J Cardiol 1985;55:296—300.
[2] Bersten AD, Holt AW, Vedig AE, Skowronski GA, Baggoley CJ.
Treatment of severe cardiogenic pulmonary edema with con-
tinuous positive airway pressure delivered by face mask. N Engl
J Med 1991;325:1825—30.
[3] Takeda S, Nejima J, Takano T, Nakanishi K, Takayama M,
Sakamoto A, Ogawa R. Effect of nasal continuous positive
airway pressure on pulmonary edema complicating acute
myocardial infarction. Jpn Circ J 1998;62:553—8.
[4] Takeda S, Takano T, Ogawa R. The effect of nasal continuous
positive airway pressure on plasma endothelin-1 concentra-
tions in patients with severe cardiogenic pulmonary edema.
Anesth Analg 1997;84:1091—6.
[5] Lin M, Yang YF, Chiang HT, Chang MS, Chiang BN, Cheitlin MD.
Reappraisal of continuous positive airway pressure therapy in
acute cardiogenic pulmonary edema. Short term result and
long term follow-up. Chest 1995;107:1379—86.
[6] Pang D, Keenan SP, Cook DJ, Sibbald WJ. The effect of positive
pressure airway support on mortality and the need for intuba-
tion in cardiogenic pulmonary edema: a systemic review. Chest
1998;114:1185—92.
[7] Antonelli M, Pennisi MA, Montini L. Noninvasive ventilation in
the clinical setting—–experience from the past 10 years. Critical
Care 2005;9:98—103.
[8] Masip J, Roque M, Sanchez B, Fernandez R, Subirana M,
Exposito JA. Noninvasive ventilation in acute cardiogenic pul-
monary edema: systemic review and meta-analysis. JAMA
2005;294:3124—30.
[9] Winck JC, Azevedo LF, Costa-Pereira A, Antonelli M, Wyatt JC.
Efﬁcacy and safety of non-invasive ventilation in the treatment
of acute cardiogenic pulmonary edema: a systemic review and
meta-analysis. Crit Care 2006;10:R69.
10] Peter JV, Moran JL, Phillips-Hughes J, Graham P, Bersten AD.
Effect of non-invasive positive pressure ventilation (NPPV)
on mortality in patients with acute cardiogenic pulmonary
oedema: meta-analysis. Lancet 2006;367:1155—63.
11] Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Non-invasive ven-
tilation in acute cardiogenic pulmonary oedema. Postgrad Med
J 2005;81:637—43.
12] Task Force for Diagnosis and Treatment of Acute and Chronic
Heart Failure 2008 of European Society of Cardiology, Dick-
stein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski
P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D,
Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, et al.
ESC Guidelines for the diagnosis and treatment of acute and
chronic heart failure 2008: the Task Force for the Diagnosis and
Treatment of Acute and Chronic Heart Failure 2008 of the Euro-
pean Society of Cardiology. Developed in collaboration with the
Heart Failure Association of the ESC (HFA) and endorsed by the
European Society of Intensive Care Medicine (ESICM). Eur Heart
J 2008; 29:2388—442.
13] Carlucci A, Richard JC, Wysocki M, Lepage E, Brochard
L. Noninvasive versus conventional mechanical ventilation.
An epidemiologic survey. Am J Respir Crit Care Med
2001;163:874—80.
14] Tallman TA, Peacock WF, Emerman CL, Lopatin M, Blicker JZ,
Weber J, Yancy CW. ADHERE Registry. Noninvasive ventilation
outcomes in 2430 acute decompensated heart failure patients:
an ADHERE Registry Analysis. Acad Emerg Med 2008;15:355—62.
15] Sato N, Kajimoto K, Asai K, Mizuno M, Minami Y, Nagashima
M, Murai K, Muanakata R, Yumino D, Meguro T, Kawana M,
Nejima J, Satoh T, Mizuno K, Tanaka K, et al. Acute decompen-
sated heart failure syndromes (ATTEND) registry. A prospective
1[
[
[
[
[
[
[
[
[
[
[
[
[14
observational multicenter cohort study: rationale, design, and
preliminary data. Am Heart J 2010;159:949—55.
16] Ambrosino N, Foglio K, Rubini F, Clini E, Nava S, Vitacca M.
Non-invasive mechanical ventilation in acute respiratory fail-
ure due to chronic obstructive pulmonary disease: correlates
for success. Thorax 1995;50:755—7.
17] Poponick JM, Renston JP, Bennett RP, Emerman CL. Use of a
ventilator support system (BiPAP) for acute respiratory failure
in the emergency department. Chest 1999;116:166—71.
18] Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam
MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G,
Tavazzi L. International Working Group on Acute Heart Failure
Syndromes. Acute heart failure syndromes: current state and
framework for future research. Circulation 2005;112:3958—68.
19] Nieminen MS, Harjola VP. Deﬁnition and epidemiology of acute
heart failure syndromes. Am J Cardiol 2005;96:5G—10G.
20] Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa
T, Yokoyama H, Tanaka K, Mizuno K, Nejima J, Kinoshita
M. Effects of carperitide on the long-term prognosis of
patients with acute decompensated chronic heart failure:
the PROTECT multicenter randomized controlled study. Circ J
2008;11:1787—93.21] Rossinen J, Harjola VP, Siirila-Waris K, Lassus J, Melin J,
Peuhkurinen K, Nieminen MS. The use of more than one
inotrope in acute heart failure is associated with increased
mortality: a multi-centre observational study. Acute Card Care
2008;10:209—13.
[A. Shirakabe et al.
22] Yan AT, Bradley TD, Liu PP. The role of continuous positive
airway pressure in the treatment of congestive heart failure.
Chest 2001;20:1675—85.
23] Masip J, Betbese AJ, Paez J, Vecilla F, Canizares R, Padro
J, Paz MA, de Otero J, Ballús J. Non-invasive pressure sup-
port ventilation versus conventional oxygen therapy in acute
pulmonary edema: a randomized trial. Lancet 2000;356:
2126—32.
24] Levitt MA. A prospective, randomized trial of BiPAP in severe
acute congestive heart failure. J Emerg Med 2001;21:363—9.
25] Girou E, Brun-Buisson C, Taille S, Lemaire F, Brochard L. Secular
trends in nosocomial infections and mortality associated with
noninvasive ventilation in patients with exacerbation of COPD
and pulmonary edema. JAMA 2003;290:2985—91.
26] Liesching T, Kwok H, Hill NS. Acute applications of non-invasive
positive pressure ventilation. Chest 2003;124:699—713.
27] Soo Hoo GW, Santiago S, Williams AJ. Nasal mechanical ventila-
tion for hypercapnic respiratory failure in chronic obstructive
pulmonary disease: determinants of success and failure. Crit
Care Med 1994;22:1253—61.
28] Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl
J. Noninvasive ventilation in acute cardiogenic pulmonary
edema. N Engl J Med 2008;10:142—51.
29] Anton A, Guell R, Gomez J, Serrano J, Castellano A, Carrasco
JL, Sanchis J. Predicting the result of noninvasive ventilation
in severe acute exacerbations of patients with chronic airﬂow
limitation. Chest 2000;117:828—33.
